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Background On 31 December, 2019, the World Health Organization China Country Office was 
informed of cases of pneumonia of unknown aetiology. Since then, there have been over 75,000 
cases globally of the 2019 novel coronavirus (COVID-19), 2000 deaths, and over 14,000 cases 
recovered. Outbreaks of novel agents represent opportunities for clinical research to inform real-
time public health action. In 2018, we conducted a systematic review to identify priority research 
questions for Severe Acute Respiratory Syndrome-related coronavirus (SARS-CoV) and Middle 
East Respiratory Syndrome-related coronavirus (MERS-CoV). Here, we review information 
available on COVID-19 and provide an evidenced-based framework for priority clinical research 
in the current outbreak. 
Methods Three bibliographic databases were searched to identify clinical studies published on 
SARS-CoV and MERS-CoV in the outbreak setting. Studies were grouped thematically 
according to clinical research questions addressed. In February 2020, available information on 
COVID19 was reviewed and compared to the results of the SARS-CoV and MERS-CoV 
systematic review. 
Results From the research objectives for SARS-CoV and MERS-CoV, ten themes in the 
literature were identified: Clinical characterisation, prognosis, diagnosis, clinical management, 
viral pathogenesis, epidemiological characterisation, infection prevention and 
control/transmission, susceptibility, psychosocial, and aetiology. For COVID19, some 
information on clinical presentation, diagnostic testing, and aetiology is available but many 
clinical research gaps have yet to be filled. 
Conclusions Based on a systematic review of other severe coronaviruses, we summarise the 
state of clinical research for COVID-19, highlight the research gaps, and provide 
   
 
   
 
2 
recommendations for the implementation of standardised protocols. Data based on 
internationally standardised protocols will inform clinical practice real-time. 
On 31 December 2019, the World Health Organization China Country Office was informed of 
cases of pneumonia of unknown etiology detected in Wuhan City, China. Shortly after, the 
National Health Commission China reported that the outbreak was associated with exposures in a 
seafood market in Wuhan. Chinese authorities then isolated and identified a novel coronavirus and 
shared the genetic sequence on 12 January 2020 [1]. Phylogenetic analysis showed that the novel 
virus falls into the betacoronavirus family, with about 86% similarity to a bat SARS-like 
coronavirus [2]. Human-to-human transmission of the virus has been confirmed [3]. As of 18 
February 2020, there have been 75,161 cases in 29 countries with 2,008 deaths. Currently, the 
disease caused by 2019 novel coronavirus has been referred to as COVID-19, and the virus SARS-
CoV-2. 
Outbreaks, especially of novel agents, create a pressing need to collect data on clinical 
characterization, treatment, and validation of new diagnostics to inform rapid public health 
response. In 2018, we conducted a systematic review to identify the most common clinical research 
questions asked during outbreaks of SARS-CoV and MERS-CoV. We identified ten major clinical 
questions and provided recommendations for standardised protocol study designs that should be 
designed in the case of a new outbreak of a novel respiratory pathogen. Here, we review the 
currently available information on COVID-19 to determine which clinical questions from the 
systematic review findings have already been addressed, what information is lacking, and compare 
COVID-19 to SARS-CoV and MERS-CoV. 
METHODS 
Overview of methodology for 2018 SARS-CoV and MERS-CoV systematic review 
We included any original study included conducted in a clinical setting during an acute outbreak 
of MERS and SARS but limited the SARS studies to those published during the SARS epidemic 
and (16 November 2002 through 5 July 2003) and 18 months thereafter to identify clinical 
questions relevant during the acute phases of the outbreak. Therefore, for SARS studies, the last 
publication date considered for full text review was 31 December 2004. There was no publication 
date restriction for MERS studies as outbreaks were ongoing. 
Search terms to capture observational study designs such as cohort studies, cross-sectional studies, 
case-control studies, and case series were adapted from the Scottish Intercollegiate Guidelines 
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Network (SIGN) search filters [4]. Search terms on diagnosis and prognosis were adapted from 
PubMed clinical query search filters provided in the PubMed Help manual [5]. To capture studies 
that were conducted in the epidemic or outbreak setting, subject headings such as “disease 
outbreaks”, “epidemics”, “pandemics”, etc. were included. 
We applied our inclusion and exclusion criteria (Table 1) for both title and abstract screening and 
subsequently full text screening. Following data extraction, the objectives of the included studies 
were grouped thematically. Within each theme, articles with objectives that represented similar 
research questions were summarised. 
[Table 1] 
Methodology for review of the 2019 novel coronavirus 
As this outbreak is in its initial stages, we reviewed resources such as: The World Health 
Organization Disease Outbreak News, Ministry of Health websites from affected countries, the 
Center for Disease Control’s Morbidity and Mortality Weekly report (MMWR), ProMED, and 
publications found on PubMed. For PubMed searches, the search term “novel AND coronavirus” 
was used, with a date range starting at 1 January 2020. The search was conducted on 20 February 
2020. References of articles found through these searches were also reviewed. Only studies 
conducted in the clinical settings were included and single case reports were excluded.  We 
compared our findings to the 2018 systematic review on SARS and MERS to determine which 
questions have already been addressed, what information is lacking, and provide recommendations 
for data sharing and clinical study designs to be conducted during the current outbreak.  We 
grouped the results thematically from reviewing available resources on the novel coronavirus 
based on their relevance to the previously identified ten clinical questions. 
Role of the funding source 
No funding body had any role in study design, in the collection, analysis, and interpretation of 
data; in the writing of the report; nor in the decision to submit the paper for publication. 
RESULTS 
2018 SARS-CoV and MERS-CoV systematic review 
A total of 124 studies (71% on SARS) were included for the final review and data extraction. All 
were conducted in a hospital setting. After thematically coding the objectives of the 124 studies, 
ten key themes emerged: Clinical characterisation, prognosis, diagnosis, clinical management, 
viral pathogenesis, epidemiological characterisation, infection prevention and 
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control/transmission, susceptibility, psychosocial, and aetiology. Originally, infection prevention 
and control and transmission were grouped separately. However, they were combined as most of 
the papers in the “transmission” category were concerned with transmission to hospital workers. 
Of note, only 16% of SARS articles were published before the end of the outbreak. Table 2 defines 
the key clinical research questions identified from each theme. This table was modelled after a 
publication describing harmonisation of Zika virus protocols [6]. Themes appear in order based on 
how many SARS and MERS articles attempted to address a question within that theme.  
[Table 2] 
COVID-19 
Current state of knowledge for 2019-COVID-19 
Here, we answer what clinical information is currently known about the novel coronavirus, using 
the above questions as a framework. 
What is the clinical presentation and spectrum of disease? 
The first aggregated patient data comes from a publication by Chaolin Huang and colleagues, 
who described clinical features of 41 admitted hospital patients, 6 of whom died. They collected 
data using an adaptation of  International Severe Acute Respiratory and Emerging Infection 
Consortium’s (ISARIC) /World Health Organisation (WHO)  internationally standardised data 
collection forms, updated for use with the novel coronavirus (https://isaric.tghn.org/novel-
coronavirus/). They report that the novel coronavirus presentation resembles that of SARS: a 
viral pneumonia with fever, cough, dyspnoea, and fatigue. They also found a high concentration 
of cytokines in critically ill patients, compared to less severe cases[7]. Chen, Wang, and Kui et 
al. reported data for 99, 138, and 137 patients respectively. All reported similar symptoms to the 
Huang article: fever, cough, shortness of breath, and fatigue. Lymphocytopenia reported among 
all authors[8–10]. Chen et al. and Wang et al. also reported elevated lactate dehydrogenase levels 
in many patients. Wang et al. report that median hospital stay was 10 days for those discharged 
alive. Unlike SARS and MERS, there seems to be less presentation of gastrointestinal symptoms. 
One report of pregnant patients demonstrated similar symptomology to non-pregnant patients. 
They also established that there was no evidence of vertical transmission to the child [11]. In the 
only study of infants with COVID-19, Wei et al. reported fever and upper respiratory symptoms 
common among nine infants. All infants were infected via family clusters [12]. Finally, 
radiological studies attempted to characterise the course of disease in chest imaging. Pan et al. 
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report peak lung involvement at 10 days on CT studies[13].  Of note is a case series by Xie et al. 
that reported ground glass opacity in five patients with initial negative RT-PCR findings but 
suspected COVID-19.  They were later confirmed to be infected[14]. Overall, clinical 
characterisation studies commonly found bilateral involvement with ground glass opacity, though 
a range of presentations were reported [8–10,15]. 
What are the risk factors for death or severe illness? 
While risk factors for death and severe illness cannot be firmly established without large groups 
of patient data and multi-variable adjusted methods, some studies report similar risk factors 
among cohorts. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team in 
China analyzed data for over 44,000 patients [16]. Being over age 80, male, and having 
comorbid conditions were each associated with increased risk of mortality. In smaller studies, 
similar results were found. Chen et al., Wang et al., and Kui et al. report more cases of severe 
illness among older patients and patients with co-morbidities [8–10]. Chen et al. also report that 
characteristics of patients who died corresponded well with the MuLBSTA, a warning model for 
predicting morality in viral pneumonia [17]. It includes indexes such as multi-lobular infiltration, 
lymphopenia, bacterial co-infection, smoking, hypertension, and age. 
What treatments are effective (including the roles of antivirals and steroids)? 
In the publication by Chaolin Huang and colleagues, antibiotics and oseltamivir, and oxygen 
support were administered to some patients. Corticosteroids were used if patients were diagnosed 
with severe community acquired pneumonia [7]. Chen et al. reported antiviral, antibiotic, and non-
invasive mechanical ventilation use but did not provide comparisons or suggestions for guidelines 
[8]. Kui et al. determined that use of systemic corticosteroids in their cohort did not show benefits, 
but early respiratory support improved outcomes[10]. In addition to a randomised controlled trial 
of lopinavir/ritonavir in adults hospitalised with COVID-19 [ChiCTR2000029308] [18], over 80 
clinical trials are expected to determine therapeutic options [19]. 
What is the optimal diagnostic test for detecting the virus? 
Several diagnostic tests for the novel coronavirus have been developed. Of note are those by 
Corman and colleagues [20] and by Hong Kong University School of Medicine [21]. The World 
Health Organization has provided preliminary guidance on specimen collection and shipment as 
well as reporting [22]. All information on diagnostic testing can be found at the WHO’s technical 
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guidance site (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-
guidance/laboratory-guidance). 
What is the duration of viral shedding? 
Zou et al. obtained upper respiratory specimens from 18 patients in Zhuhai, China. Highest viral 
loads were detected soon after symptom onset, with higher loads in the nose and throat. They 
suggest that the shedding pattern of SARS-CoV-2 resembles patients with influenza. 
Asymptomatic patients were also found to have nasopharyngeal viral loads similar to symptomatic 
patients [23]. Additionally, Y. Zhang et al. found live virus in stool samples [24]. Zhou and 
colleagues have reported positive virus results from both oral swabs and bronchoalveolar lavage 
samples, while bronchoalveolar lavage samples yielded higher viral copies [25]. W. Zhang et al. 
report the presence of viral load in oral swabs, anal swabs, and blood, suggesting respiratory, fecal-
oral, and blood transmission[26]. To et al. report serial saliva samples among 12 patients, with 
declining viral RNA levels after hospitalization. However, one patient showed viral shedding in 
saliva up to 11 days[27]. 
What characteristics define a “case”? 
The World Health Organization has provided a case definition in their interim surveillance 
guidance for the novel coronavirus[28]. The definition includes patients with a severe acute 
respiratory infection (SARI) with relevant travel history within 14 days of illness or a healthcare 
worker caring for those with SARI. 
What are the risk factors which pre-dispose health care workers to infection or transmission? 
Currently, there are no data on what clinical activities are associated with an increased risk to 
health care workers. As of 14 February 2020, over 1700 health care workers have been infected 
[29]. The World Health Organization has provided interim guidelines for infection prevention and 
control [30]. 
What are the risk factors for infection in the patient population? 
Currently, it is unclear whether certain demographics of the population are more susceptible to 
infection with the novel coronavirus. Most initial cases had contact with Wuhan’s Huanan Seafood 
Market, the suspected source of the outbreak, or had contact with those who had visited the market 
[1]. 
What is the causative agent of disease? 
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Sequencing analysis from lower respiratory tract samples from bronchoalveolar lavage identified 
the novel coronavirus. Genomes were released on GISAID.org. Due to similarities with related 
viruses, a bat reservoir is suspected [25]. 
What are the psychosocial consequences of infection with the virus? 
Currently, there are no data on the psychosocial impacts of infection, hospitalization, or quarantine 
among affected patients and healthcare workers. 
DISCUSSION 
We summarise the available clinical information on COVID-19, using results from a systematic 
review on SARS and MERS as a framework. As highlighted by David Heymann in a recent Lancet 
Commentary, rapid action by clinicians and scientists to share data has made it possible to identify 
a causative agent, design and implement a diagnostic test, as well as begin to understand patient 
presentation[31]. As outlined above, there is much work to be done on understanding the clinical 
picture of the novel coronavirus. The World Health Organization R&D Research Blueprint and 
the Global Research Collaboration for Infectious Disease Preparedness (GLOPID-R) have 
identified similar research priorities as those we identified from our systematic review. 
Overlapping priorities include understanding viral pathogenesis, clinical characterisation studies, 
infection prevention and control, and candidate therapeutics [32]. 
To facilitate answering these key clinical questions, we suggest the following study designs (Table 
3). Notably, the World Health Organization released a cases and contacts investigation protocol 
called “The First Few X (FFX)”. It involves prospective case finding and follow-up to gain an 
early understanding of key clinical, epidemiological, and virologic characteristics of the first cases 
of COVID-19 in a given country. They have also released a protocol to assess risk factors for 
infection among health care workers.  
[Table 3] 
What is the clinical presentation and spectrum of disease?  
In terms of clinical presentation, early recognition of symptoms and disease progression also 
allows for rapid isolation, early clinical care and limits onward transmission. WHO and ISARIC 
have released an updated version of their case report form (CRF) specifically for COVID-19. This 
can be used to collect anonymised, standardised clinical data to start to inform our understanding 
of the presentation and natural history of COVID-19. This CRF is being rolled out as a tool for 
public health and may or may not require ethical approval according to local regulations. A more 
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in-depth characterisation, with the collection of serial biological samples through a research 
protocol and informed consent can be obtained through the ISARIC/WHO Clinical 
Characterization Protocol. This a standardised, prospective, observational study for the rapid 
investigation of patients with severe acute infections. The protocol was designed to characterise 
host and pathogen features, triage and treatment of disease [33]. The WHO FFX protocol, 
described above, may be used for the earliest cases to identify key clinical characteristics in real-
time.  The current clinical characterisation articles are a start to our understanding of the clinical 
presentation and spectrum of disease but much larger cohorts are needed for greater precision 
around estimates and to undertake prognostic and risk factor analyses. Based on the SARS and 
MERS systematic review, further clinical research in this area should include if and how 
symptomology, laboratory findings, and imaging studies differ between demographic groups (ie. 
adults vs. children, immunosuppressed patients). 
What are risk factors for death or severe illness? 
Based on recent data, male gender, advancing age and co morbidities seem to be associated with 
death and severe illness [16]. Understanding prognostic factors for death or severe illness helps 
hospitals and public health authorities determine resource allocation [34–36]. During the SARS 
epidemic, risk factors for mortality were advanced age, co-morbidities, and initial high 
inflammatory laboratory markers [37,38]. Similarly, for MERS, advanced age and co-morbidities 
are predictors of severe illness and death [39]. 
Many studies identified from the MERS and SARS systematic review were retrospective cohort 
studies and poor outcomes were assessed 21-30 days from symptom onset. In designing protocols 
for mortality or severe illness risk factors for COVID-19, case-control studies or prospective 
cohort studies should be used with an end-point at 90 days, so as not to miss late deaths. Whatever 
the optimal end-point for assessing outcome, standardising this outcome measure across studies 
will allow researchers to contribute to core data sets. 
What treatments are effective (including the role of antivirals and steroids)? 
While there is some preliminary descriptive data on clinical management, randomized controlled 
trials are needed to determine the best treatment options for COVID-19. For now, the World 
Health Organization has issued interim guidelines for clinical management, adapted from their 
guidance for MERS-CoV. It includes recommendations for early recognition, early supportive 
therapy (oxygen, fluids, empiric antimicrobials) and against routine use of systemic 
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corticosteroids unless indicated for another reason. They also provide guidelines for cases of 
septic shock[30]. Clinical trials to test therapeutic efficacy are ongoing, such as a trial of 
lopinavir/ritonavir (https://www.pharmaceutical-technology.com/analysis/coronavirus-mers-cov-
drugs/). More studies are expected soon [19]. 
Most of studies identified in the SARS and MERS review were descriptive treatment studies. 
These observational studies are practical in the fast-paced outbreak setting, as they are easier 
than randomised controlled trials (RCTs) to design and require less administrative effort. 
However, when it comes to treatment, RCTs provide the best primary evidence for medical 
practice [40]. Among these studies, there was great heterogenicity for testing efficacy of specific 
treatments. This reflects the lack of global research coordination in delivering medical 
countermeasures during the MERS outbreaks and the SARS epidemic. This should be kept in 
mind when designing treatment protocols for COVID-19 and is being addressed by WHO. 
The RCT on Ebola therapeutics in the Democratic Republic of the Congo is evidence that 
conducting clinical therapeutics research is possible in the context of an outbreak [41]. 
The WHO has released a Master Protocol for a multi-centre, adaptive, randomized, double-blind 
placebo controlled clinical trial to evaluate safety and efficacy of therapeutic agents for the 
treatment of hospitalized patients with COVID-19. Using a Master Protocol across international 
sites can speed the implementation of clinical trials and quickly inform treatment options 
(https://www.who.int/blueprint/priority-diseases/key-action/multicenter-adaptive-RCT-of-
investigational-therapeutics-for-COVID-19.pdf?ua=1). 
What is the optimal diagnostic test? 
The rapid development of a diagnostic test for COVID-19 was a critical development and the 
result of international collaboration. As the outbreak progresses, it is important to continue 
monitoring diagnostic validity, such as sensitivity, specificity, positive predictive value, and 
negative predictive value. During an outbreak or epidemic, it is important to also validate 
diagnostic tests in low prevalence areas, as predictive values may change [42].  
What is the duration of viral shedding? 
Understanding the duration of viral shedding and the shedding profile from different anatomical 
sites are key for both diagnosis and instituting infection prevention and control measures [43]. 
Current data suggest that SARS-CoV-2 viral loads are high at the beginning of symptom onset, 
are found in upper respiratory specimens and stool specimens, and are detectable in 
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asymptomatic patients at levels similar to symptomatic patients [23]. One SARS study revealed 
that viral detection peaked at 2 weeks after onset for respiratory specimens and 2-3 weeks for 
stool and rectal specimens. The shedding peak in urine occurred around weeks 3-4. Rarely did 
patients shed virus 6 weeks after onset, however it was documented in a few stool 
specimens[44]. 
To evaluate the shedding profile during the COVID-19 outbreak, the ISARIC/WHO Clinical 
Characterization protocol can be adapted to prospectively and systematically collect serial 
samples from patients with suspected infection[45],[33]. As with studies on SARS and MERS, 
serial samples should be collected from multiple body sites, including urine, faecal, and 
nasopharyngeal samples. 
What characteristics define a “case”? 
In an outbreak, if multiple sites adopt a standardised protocol such as the ISARIC/WHO Clinical 
Characterization protocol to describe cases, case definitions could be created rapidly to inform 
accurate reports on incidence and prevalence. Developing criteria for confirmed cases is usually 
based on laboratory diagnosis. The World Health Organization has provided an interim case 
definition, and it will likely evolve as more data is shared on patient presentation. 
What risk factors pre-dispose health care workers to infection or transmission? 
Over 1,700 healthcare workers in Wuhan have been diagnosed with COVID-19 and there is no 
research available as to how this happened. Both MERS and SARS viruses showed nosocomial 
transmission amplification in the health care setting [46]. During the SARS epidemic, 21% of the 
infected patients were health care workers, and in some countries, this rate was as high as 50% 
[47]. Risk of SARS infection was associated with inconsistent use of personal protective 
equipment, and less than 2 hours of infection control training[48]. During the 2015 South Korea 
MERS outbreak, 44% of the 186 cases were patients that had been exposed to nosocomial 
transmission in hospitals, and 83% of total transmission events were due to five super spreading 
events in hospitals [49]. The recently released WHO protocol for evaluating risks to health care 
workers should be implemented as soon as possible to prevent future health care worker 
infections. 
What are the risk factors for infection (in patient population)? 
   
 
   
 
11 
The suspected major risk factors for COVID-19 are visiting the Wuhan market or being in 
contact with someone who had visited the market. The above-mentioned WHO FFX protocol can 
be used globally to assess risk factors for infection. 
What are the psychosocial consequences of infection with the virus? 
In the 2018 SARS and MERS systematic review, only three studies with a psychosocial focus 
were identified. However, integrating social science research into clinical and epidemiological 
research during an outbreak can help inform the need for psychologists, psychiatrists, and social 
workers. Especially in diseases with human-to-human transmission, the effect of stigma and 
quarantine on mental health cannot be underestimated. Psychosocial manifestations can be 
explored with mixed methods studies. 
What is the causative agent of disease? 
Because of rapid data sharing and laboratory protocols by the Chinese health officials and the 
World Health Organization, the causative agent of the novel coronavirus was rapidly identified. 
Limitations 
Our systematic review summarises the questions that are answered in the context of new 
outbreaks, but this methodology cannot tell us what questions should be answered. However, we 
propose this as a proxy for ensuring key clinical questions are addressed early in an outbreak. We 
have summarised key knowledge gaps for COVID19, but we do not intend to suggest that this is 
an exhaustive list. Many of the most important discoveries hinge on the creativity and innovation 
to identify new questions. In this new outbreak, we need new ideas to build on the foundations that 
we have comprehensively summarised in this article. 
Implications for practice 
The suggested study designs above can be used to inform standardised research protocols and 
define data sets that should be collected by hospitals around the world, if they are affected by 
COVID-19. As in any outbreak setting, priorities of local clinicians and public health authorities 
should be considered, especially in countries that integrate traditional medicine with Western 
medicine. Researchers may consider adopting a tiered approach as ISARIC has with the Clinical 
Characterisation protocols. The tiered approach allows sites to determine how much data or 
samples they can collect given their (limited) resources. This allows health care centres in low and 
middle-income countries to be represented in the data. Global solidarity is needed in the clinical 
research community as we may face the next pandemic of the 21st century. We all benefit from 
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the data collected and shared. WHO have launched a clinical data collection platform for COVID-
19 via the International Health Regulations and hope that member states will share their data. This 
uses an ISARIC WHO co-created CRF for COVID 19. 
CONCLUSIONS 
Thanks to lessons learned from SARS and MERS, the international public health and research 
community has been able to rapidly respond to the emergence of this novel coronavirus. Based on 
a 2018 systematic review of SARS and MERS common clinical research questions, we provide a 
summary of the state of current clinical knowledge for the COVID-19, demonstrate what clinical 
research gaps still need to be filled, and provide recommendations on study designs. Many of the 
identified gaps, such as viral pathogenesis, clinical characterisation, infection prevention, and 
candidate therapeutics overlap with gaps identified the WHO’s R&D Blueprint research roadmap. 
If health care facilities around the world collect standardised patient data and quickly share it, it is 
likely that these core clinical research questions can be answered in real-time to inform clinical 
practices for COVID-19. 
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Table 1. Inclusion and exclusion criteria for SARS-CoV and MERS-CoV systematic review 
Inclusion criteria Exclusion criteria 
Studies must be: 1) the main objective was not the study of SARS-CoV 
or MERS-CoV 
• Focused SARS-CoV or MERS-
CoV 2) the study was not conducted primarily in a clinical 
setting (i.e. population epidemiology studies, in-vitro 
studies, surveillance studies were excluded) 
• Conducted in a clinical setting 
• Conducted on humans  
Study designs considered: Observational 
studies (prospective cohort, retrospective 
cohort, case-control, case-series) and cross-
sectional studies.  
3) the study was not conducted in an outbreak setting 
or did not analyse data that was collected in an 
outbreak setting  
 4) non-human studies 
5) the sample size was less than 4   
6) the study was not original 
 
Table 2. Themes and key clinical questions asked during outbreaks of SARS and MERS 
Theme Key question(s) Objective 
Clinical 
characterisation 
What is the clinical 
presentation and 
spectrum of disease? 
Determine symptomology, progression of 
disease, laboratory findings, and radiological 
features in different patient groups (adults vs. 
children, immunosuppressed patients) and 
identify early presenting symptoms 
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Prognosis What are the risk factors 
for death or severe 
illness? 
Identify factors such as comorbidities, 
demographic factors, test parameters, etc. that 
predict death, ICU admission, etc. 
Clinical management What treatments are 
effective for 
MERS/SARS patients? 
Determine the role of antiviral treatments, 
steroid treatments, or combination in 
comparison to supportive therapy 
What is the role of 
antivirals in treatment? 
What is the role of 
steroids in treatment? 
Diagnosis What is the optimal 
diagnostic test for 
detecting the virus? 
Evaluate sensitivity/specificity/positive 
predictive value/negative predictive value of 
different diagnostic assays such as real-time 
RT-PCR and ELISA 
Viral pathogenesis What is the duration of 
viral shedding? 
Determine the viral shedding profiles over 
time and in different body fluids 
Epidemiological 
characterisation 
What characteristics 
define a “case”? 
Develop criteria for suspected, probable, and 
confirmed cases 
Infection prevention 
and control / 
Transmission 
What are the risk factors 
which pre-dispose health 
care workers to infection 
or transmission? 
Determine the activities or prevention 
measures that are correlated with protection or 
infection in health care workers 
Susceptibility What are the risk factors 
for infection? (patient 
population) 
Determine the risk factors for patient 
infection, in the community and health care 
setting 
Psychosocial What are the 
psychosocial 
consequences of infection 
with the virus? 
Determine effect of illness, treatment, and 
isolation procedures on the psychological and 
social well-being of those infected 
Table 3. Recommended study designs for COVID-19 
Key question(s) Recommended study design and associated resources 
What is the clinical presentation 
and spectrum of disease? 
Patient cohorts or patient registry. 
Resource for hospitalised cases: Modified ISARIC/WHO Clinical 
Characterization protocol using new CRF form for COVID-19 
(https://isaric.tghn.org/novel-coronavirus/) 
The First Few X (FFX) WHO Protocol 
https://www.who.int/publications-detail/the-first-few-x-(ffx)-cases-
and-contact-investigation-protocol-for-2019-novel-coronavirus-
(2019-ncov)-infection) 
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What are the risk factors for 
death or severe illness? 
Case-control study or prospective cohort with outcome of death or 
another defined poor outcome 
What treatments are effective? Randomised controlled trials or adaptive trial designs 
What is the role of antivirals in 
treatment? 
WHO Master Protocol: https://www.who.int/blueprint/priority-
diseases/key-action/multicenter-adaptive-RCT-of-investigational-
therapeutics-for-COVID-19.pdf?ua=1 What is the role of steroids in 
treatment? 
What is the optimal diagnostic 
test for detecting the virus? 
Diagnostic validation studies with clinical specimens 
What is the duration of viral 
shedding? 
Prospective cohort with systematic serial collection of specimens 
Resource for hospitalised cases: ISARIC/WHO Clinical 
Characterization protocol (https://isaric.net/ccp) 
What characteristics define a 
“case”? 
Clinical or population-based cohorts 
Resource for hospitalised cases: ISARIC/WHO Clinical 
Characterization protocol (https://isaric.net/ccp) 
The First Few X (FFX) WHO Protocol 
What are the risk factors which 
pre-dispose health care workers 
to infection or transmission? 
HCW cohort studies or case-control studies 
Resource: WHO HCW risk factor protocol 
(https://www.who.int/publications-detail/protocol-for-assessment-
of-potential-risk-factors-for-2019-novel-coronavirus-(2019-ncov)-
infection-among-health-care-workers-in-a-health-care-setting) 
What are the risk factors for 
infection? (patient population) 
Patient cohort 
Resource: The First Few X (FFX) WHO Protocol 
What are the psychosocial 
consequences of infection with 
the virus? 
Mixed methods study (survey + qualitative interviews) 
What is the causative agent of 
disease? 
Laboratory based study with clinical specimens, fulfilling Koch’s 
postulates 
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